The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a best–worst scaling approach-Reference-Cited by-同舟云学术

The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a best–worst scaling approach

Published:2021-01-01 Issue:1 Volume:24 Page:846-856
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Wranik Wiesława Dominika¹²³^ORCID,Székely Ronaldo-Raul⁴^ORCID,Mayer Susanne⁵^ORCID,Hiligsmann Mickaël⁶^ORCID,Cheung Kei Long⁷^ORCID

Affiliation:

1. Faculty of Management, School of Public Administration, Dalhousie University, Halifax, Canada

2. Faculty of Medicine, Department of Community Health and Epidemiology, Dalhousie University, Halifax, Canada

3. Jean Monnet European Union Centre of Excellence, Dalhousie University, Halifax, Canada

4. Division of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

5. Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria

6. Faculty of Health Medicine and Life Sciences, School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands

7. Health Behaviour Change Research Group, Department of Health Sciences, College of Health and Life Sciences, Brunel University London, London, UK

Funder

Dalhousie University

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1946326

Reference53 articles.

1. The 2018 decision to establish an Advisory Council on adding pharmaceuticals to universal health coverage in Canada

2. Government of Canada. A prescription for Canada: achieving Pharmacare for all. Final Report of the Advisory Council on the Implementation of National Pharmacare [Internet]. Ottawa (Canada): Government of Canada; 2019 [cited 2021 June 15]. Available from: https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/implementation-national-pharmacare/final-report.html

3. New Public Governance in health care: Health Technology Assessment for Canadian pharmaceuticals

4. The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Best–Worst Scaling Study of the General Population's Preferences for Activities in Living Arrangements for Persons With Dementia;The Patient - Patient-Centered Outcomes Research;2023-12-08

2. Informing a cost-effectiveness threshold for Saudi Arabia;Journal of Medical Economics;2023-01-18